News

Story March 4 - Atara Biotherapeutics: While the biotech navigates the fallout from the FDA’s move to halt trials of its allogeneic T-cell immunotherapy Ebvallo and a CAR-T candidate ...
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________ SCHEDULE 14 A Proxy Statement Pursuant to Section 14 of the Securities Exchange Act of ...